[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542510":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":45,"centralContacts":50,"locations":56,"responsibleParty":323,"collaborators":44,"id":325,"slug":44,"hasResults":326,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":44,"eligibilityCriteria":330,"healthyVolunteers":326,"sex":331,"minAge":332,"maxAge":44,"enrollmentInfo":333,"targetDuration":44,"studyType":336,"phases":337,"briefSummary":339,"conditions":340,"keywords":44,"overallStatus":59,"whyStopped":44,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":356},{"fullName":5,"class":6},"Ajax Therapeutics, Inc.","INDUSTRY",[8,14,18,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Dose A of AJ1-11095 taken orally by patients.",[13],"Drug: AJ1-11095",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Dose B of AJ1-11095 taken orally by patients.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","Dose C of AJ1-11095 taken orally by patients.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","Dose D of AJ1-11095 taken orally by patients.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Cohort 5","Dose E of AJ1-11095 taken orally by patients.",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Dose Expansion Cohort 1","Candidate RP2D of AJ1-11095 taken orally by patients.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Dose Expansion Cohort 2","Alternative candidate RP2D of AJ1-11095 taken orally by patients.",[13],[39],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","AJ1-11095","Type II JAK2 Inhibitor",[9,15,19,23,27,31,35],null,[46],{"name":47,"affiliation":48,"role":49},"John Mascarenhas, M.D.","Mt. Sinai","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":44,"email":55},"David Steensma, M.D.","CONTACT","917-410-7250","david@ajaxtherapeutics.com",[57,74,88,101,115,125,139,153,165,175,189,203,216,230,242,255,266,279,290,298,312],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Stanford Cancer Institute","RECRUITING","Palo Alto","California","94304","United States",{"type":65,"coordinates":66},"Point",[67,68],-122.14302,37.44188,{"lat":68,"lon":67},[71],{"name":72,"role":53,"phone":73,"phoneExt":44,"email":44},"William Shomali, MD","650-498-6000",{"facility":75,"status":59,"city":76,"state":77,"zip":78,"country":63,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Moffitt Cancer Cancer Center","Tampa","Florida","33612",{"type":65,"coordinates":80},[81,82],-82.45843,27.94752,{"lat":82,"lon":81},[85],{"name":86,"role":53,"phone":87,"phoneExt":44,"email":44},"Andrew Kuykendall, MD","813-745-4639",{"facility":89,"status":59,"city":90,"state":91,"zip":92,"country":63,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"University of Kansas Medical Center","Kansas City","Kansas","66160",{"type":65,"coordinates":94},[95,96],-94.62746,39.11417,{"lat":96,"lon":95},[99],{"name":100,"role":53,"phone":44,"phoneExt":44,"email":44},"Abdulraheem Yacoub, MD",{"facility":102,"status":59,"city":103,"state":104,"zip":105,"country":63,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":65,"coordinates":107},[108,109],-71.05977,42.35843,{"lat":109,"lon":108},[112],{"name":113,"role":53,"phone":114,"phoneExt":44,"email":44},"Gabriela Hobbs, MD","617-724-1124",{"facility":116,"status":59,"city":103,"state":104,"zip":117,"country":63,"cosmosGeoPoint":118,"geoPoint":120,"contacts":121},"Dana Farber Cancer Institute","02115",{"type":65,"coordinates":119},[108,109],{"lat":109,"lon":108},[122],{"name":123,"role":53,"phone":124,"phoneExt":44,"email":44},"Jacqueline Garcia, MD","617-632-1906",{"facility":126,"status":59,"city":127,"state":128,"zip":129,"country":63,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"University of Michigan","Ann Arbor","Michigan","48109",{"type":65,"coordinates":131},[132,133],-83.74088,42.27756,{"lat":133,"lon":132},[136],{"name":137,"role":53,"phone":138,"phoneExt":44,"email":44},"Kristen Pettit, MD","734-647-2829",{"facility":140,"status":59,"city":141,"state":142,"zip":143,"country":63,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Washington University School of Medicine","St Louis","Missouri","63110",{"type":65,"coordinates":145},[146,147],-90.19789,38.62727,{"lat":147,"lon":146},[150],{"name":151,"role":53,"phone":152,"phoneExt":44,"email":44},"Stephen Oh, MD","314-362-8814",{"facility":154,"status":59,"city":155,"state":155,"zip":156,"country":63,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"David H. Koch Center for Cancer Care at Memorial Sloan Kettering","New York","10021",{"type":65,"coordinates":158},[159,160],-74.00597,40.71427,{"lat":160,"lon":159},[163],{"name":164,"role":53,"phone":44,"phoneExt":44,"email":44},"Raajit Rampal, MD",{"facility":166,"status":59,"city":155,"state":155,"zip":167,"country":63,"cosmosGeoPoint":168,"geoPoint":170,"contacts":171},"Icahn School of Medicine at Mount Sinai","10029",{"type":65,"coordinates":169},[159,160],{"lat":160,"lon":159},[172],{"name":173,"role":53,"phone":174,"phoneExt":44,"email":44},"John Mascarenhas, MD","212-241-8839",{"facility":176,"status":59,"city":177,"state":178,"zip":179,"country":63,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":65,"coordinates":181},[182,183],-80.84313,35.22709,{"lat":183,"lon":182},[186],{"name":187,"role":53,"phone":188,"phoneExt":44,"email":44},"Michael Grunwald, MD","980-442-4363",{"facility":190,"status":59,"city":191,"state":192,"zip":193,"country":63,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"University of Cincinnati","Cincinnati","Ohio","45221",{"type":65,"coordinates":195},[196,197],-84.51439,39.12711,{"lat":197,"lon":196},[200],{"name":201,"role":53,"phone":202,"phoneExt":44,"email":44},"Eric Vick, MD","513-213-3203",{"facility":204,"status":59,"city":205,"state":192,"zip":206,"country":63,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"The Ohio State University Comprehensive Cancer Center","Columbus","43210",{"type":65,"coordinates":208},[209,210],-82.99879,39.96118,{"lat":210,"lon":209},[213],{"name":214,"role":53,"phone":215,"phoneExt":44,"email":44},"Uma Borate, MD","614-685-9828",{"facility":217,"status":59,"city":218,"state":219,"zip":220,"country":63,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":65,"coordinates":222},[223,224],-95.36327,29.76328,{"lat":224,"lon":223},[227],{"name":228,"role":53,"phone":229,"phoneExt":44,"email":44},"Prithviraj Bose, MD","713-792-7747",{"facility":231,"status":59,"city":232,"state":44,"zip":44,"country":233,"cosmosGeoPoint":234,"geoPoint":238,"contacts":239},"AP-HP Hopital Saint-Louis","Paris","France",{"type":65,"coordinates":235},[236,237],2.3488,48.85341,{"lat":237,"lon":236},[240],{"name":241,"role":53,"phone":44,"phoneExt":44,"email":44},"Jean-Jacques Kiladjian",{"facility":243,"status":244,"city":245,"state":246,"zip":44,"country":246,"cosmosGeoPoint":247,"geoPoint":251,"contacts":252},"IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola","NOT_YET_RECRUITING","Bologna","Italy",{"type":65,"coordinates":248},[249,250],11.33875,44.49381,{"lat":250,"lon":249},[253],{"name":254,"role":53,"phone":44,"phoneExt":44,"email":44},"Francesca Palandri, MD",{"facility":256,"status":244,"city":257,"state":246,"zip":44,"country":246,"cosmosGeoPoint":258,"geoPoint":262,"contacts":263},"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","Milan",{"type":65,"coordinates":259},[260,261],9.18951,45.46427,{"lat":261,"lon":260},[264],{"name":265,"role":53,"phone":44,"phoneExt":44,"email":44},"Francesco Passamonti, MD",{"facility":267,"status":59,"city":268,"state":269,"zip":44,"country":269,"cosmosGeoPoint":270,"geoPoint":274,"contacts":275},"Hospital General Universitario Gregorio Maranon","Madrid","Spain",{"type":65,"coordinates":271},[272,273],-3.70256,40.4165,{"lat":273,"lon":272},[276],{"name":277,"role":53,"phone":278,"phoneExt":44,"email":44},"Santiago Osorio-Prendes, MD","0034915868443",{"facility":280,"status":59,"city":281,"state":44,"zip":44,"country":269,"cosmosGeoPoint":282,"geoPoint":286,"contacts":287},"Hospital Clinic Barcelona","Barcelona",{"type":65,"coordinates":283},[284,285],2.15899,41.38879,{"lat":285,"lon":284},[288],{"name":289,"role":53,"phone":44,"phoneExt":44,"email":44},"Ana Moreno Triguero",{"facility":291,"status":59,"city":268,"state":44,"zip":44,"country":269,"cosmosGeoPoint":292,"geoPoint":294,"contacts":295},"Hospital Universitario Ramon y Cajal",{"type":65,"coordinates":293},[272,273],{"lat":273,"lon":272},[296],{"name":297,"role":53,"phone":44,"phoneExt":44,"email":44},"Valentin Garcia-Gutierrez",{"facility":299,"status":244,"city":300,"state":301,"zip":44,"country":302,"cosmosGeoPoint":303,"geoPoint":307,"contacts":308},"Guy's Hospital","London","UK","United Kingdom",{"type":65,"coordinates":304},[305,306],-0.12574,51.50853,{"lat":306,"lon":305},[309],{"name":310,"role":53,"phone":311,"phoneExt":44,"email":44},"Claire Harrison, MD","07939059512",{"facility":313,"status":244,"city":314,"state":301,"zip":44,"country":302,"cosmosGeoPoint":315,"geoPoint":319,"contacts":320},"Genesis Cancer Care UK Limited - Oxford","Oxford",{"type":65,"coordinates":316},[317,318],-1.25596,51.75222,{"lat":318,"lon":317},[321],{"name":322,"role":53,"phone":44,"phoneExt":44,"email":44},"Adam Mead, MD",{"type":324,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100542510",false,"NCT06343805","A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Diagnosis of PMF, post-PV MF, or post-ET MF.\n3. DIPSS Intermediate-2 or High-risk MF with ≤10% blasts, regardless of JAK2 mutation status.\n4. Estimated spleen volume ≥450cm3.\n5. MFSAF v.4.0 TSS ≥10, or at least 2 of 7 MFSAF-assessed symptoms with scores ≥3.\n6. ECOG PS of 0, 1, 2, or 3.\n7. Prior therapy with at least 1 type I JAK2 inhibitor, and either failed to achieve a response or relapsed after achieving a response.\n8. ANC ≥1.0×10\\^9\u002FL.\n9. Platelet count ≥75×10\\^9\u002FL.\n10. eGFR ≥45 mL\u002Fmin\u002F1.73m2.\n11. Serum total bilirubin ≤2.0 × upper limit of normal (ULN).\n12. AST and ALT ≤3.0 × ULN.\n13. QTcF ≤480 msec.\n\nExclusion Criteria:\n\n1. Prior splenectomy.\n2. Splenic irradiation within 3 months prior to first dose of study drug.\n3. Ongoing use of systemic corticosteroids at dose equivalent to \\>10mg\u002Fday of prednisone.\n4. Uncontrolled intercurrent illness such as an acute infection.\n5. Chronic active or acute hepatitis B or C infection.\n6. Chemotherapy in the previous 4 weeks prior to first dose of study drug (Hydrea is permitted until 5 days before starting protocol therapy).\n7. Use of a Type I JAK2 inhibitor must have been discontinued for at least 5 days or 5 half-lives prior to dosing (whichever is longer).\n8. Use of erythropoiesis stimulating agents (unless stable for \\>8 weeks).\n9. Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v 5.0).\n10. Unable or unwilling to undergo CT or MRI for spleen size imaging.\n11. Pregnant or breastfeeding.\n12. Requirement for therapy with a medication that is a strong CYP3A4 inhibitor as a concomitant medication.","ALL","18 Years",{"count":334,"type":335},76,"ESTIMATED","INTERVENTIONAL",[338],"PHASE1","AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.",[341,342,343,344,345,346],"Primary Myelofibrosis","Post-Essential Thrombocythemia Myelofibrosis","Post-Polycythemia Vera Myelofibrosis","PMF","PPV-MF","PET-MF","2026-05-08",{"date":349,"type":350},"2026-05-12","ACTUAL",{"date":352,"type":350},"2024-10-23",{"date":354,"type":335},"2027-02-15",{"name":5,"class":6},21]